S. Korea Drug Makers Slow To Enter Challenging Biosimilar Market
This article was originally published in PharmAsia News
Executive Summary
South Korea's Samsung Group has become the nation's leader in biotechnology drug biosimilars, but it still has few potential competitors
You may also be interested in...
Pipeline Acquisitions, Co-Promotion Deals, To Drive Ipsen
Ipsen’s business strategy calls for accessing external innovation across its pipeline, combined with geographic expansion, realizing the unmet potential of its marketed products and business efficiencies in manufacturing and operations.
Biden COVID-19 Plan Would Grow Domestic Manufacturing Base
The proposal, which would increase capacity for pandemic supplies, is similar to ideas President Trump embraced pre-pandemic.
People On The Move: Appointments At Sanofi, Enzymatica And Bayer
Sanofi has named the head of its new API business; Sweden's Enzymatica has hired talent from J&J and L'Oreal; and Bayer has a new transformation officer.
Need a specific report? 1000+ reports available
Buy Reports